基础医学与临床 ›› 2019, Vol. 39 ›› Issue (3): 392-395.

• 临床研究 • 上一篇    下一篇

地屈孕酮联合来曲唑治疗对子宫内膜异位症患者性激素、炎性因子、CA125及VEGF的影响

谭细凤1,李怀芳2,王玉凤1,谷雨枫1   

  1. 1. 武警浙江省总队嘉兴医院
    2. 上海同济大学附属同济医院
  • 收稿日期:2018-07-18 修回日期:2018-11-01 出版日期:2019-03-05 发布日期:2019-03-05
  • 通讯作者: 谭细凤 E-mail:tanxifeng298@163.com

Effect of dydrogesterone combined with letrozole on sex hormones, inflammatory factors, CA125 and VEGF in patients with endometriosis

  • Received:2018-07-18 Revised:2018-11-01 Online:2019-03-05 Published:2019-03-05

摘要: 目的 探讨地屈孕酮联合来曲唑治疗对子宫内膜异位症患者性激素、炎性因子、糖类抗原125(CA125)及血管内皮生长因子(VEGF)的影响。方法 选取2017年1月至2017年12月嘉兴医院收治的98例子宫内膜异位症患者作为研究对象,随机分为对照组49例和观察组49例,对照组患者只服用来曲唑(每次1片,每天1次,连用6个月),观察组合并应用来曲唑与地屈孕酮(每次1片,每天2次,连用6个月),比较两组患者的临床疗效,用放射免疫法检测两组治疗前后的促卵泡生成素(FSH)、促黄体生产素(LH)、雌激素(E2)、孕酮(P)及CA125水平,用双抗体夹心法检测白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及VEGF水平。结果 治疗6个月后,两组患者的E2、P、IL-6、TNF-α、CA125、VEGF均比治疗前显著降低(P<0.05),且观察组的E2、P、IL-6、TNF-α、CA125和VEGF均低于对照组(P<0.05)。结论 地屈孕酮联合来曲唑可有效减轻临床症状,降低子宫内膜异位症患者的E2、P、炎性因子、CA125及VEGF水平。

关键词: 关键词:地屈孕酮, 来曲唑, 子宫内膜异位症

Abstract: Objective To investigate the effects of dydrogesterone combined with letrozole on sex hormones, inflammatory factors, carbohydrate antigen 125 (CA125) and vascular endothelial growth factor (VEGF) in patients with endometriosis. Methods From January 2017 to December 2017, 98 patients with endometriosis admitted in Jia Xing hospital were randomly divided into the observation group (49 cases) and the control group (49 cases). The patients in the control group were only treated with letrozole(1 tablets, 1 times a day for 6 months). The observation group was given letrozole and megestrol acetate (1 tablets, 2 times a day for 6 months). The clinical efficacy of the two groups was compared. The levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), estrogen (E2), progesterone (P) and CA125 were detected by radioimmunoassay before and after treatment. The levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and vascular endothelial growth factor (VEGF) were detected by double antibody sandwich method before and after treatment. Results The total effective rate of the observation group was 93.88%, which was higher than that of the control group (75.51%) (P<0.05). Six months after treatment, the E2, P, IL-6, TNF-α, CA125 and VEGF of the two groups were significantly lower than before treatment, and the E2, P, IL-6, TNF-α, CA125 and VEGF of the observation group were lower than those of the control group, the differences were statistically significant (P<0.05). Conclusion Dedrogesterone combined with letrozole can effectively relieve clinical symptom, reduce the levels of E2, P, inflammatory factors, CA125 and VEGF in patients with endometriosis.

Key words: Key words: Dizogestrel, Letrozole, Endometriosis